Short-term intravenous proton pump inhibitors and histamine H2 antagonists do not negatively affect
sustained virologic response in hepatitis C cirrhotic patients treated with ledipasvir or velpatasvir
containing antiviral regimens: a case series
Reported by Jules Levin
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands
